Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

First Three Novel Biologic Suffixes Came Courtesy Of US FDA, Not Sponsors

Jan 27 2018

• By Sue Sutter

Related Content

Novel Biologics Will Get Suffixes (Or At Least One Did)

Nov 16 2017

Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss

Dec 19 2017

Novel Biologics In US Might Not Start Getting Suffixes Until August

Apr 05 2017

Hemlibra Clinical Development Timeline

Jan 27 2018

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Jan 13 2017

Biological Product Suffix Submissions Limited To 10 Candidates By US FDA

Jan 16 2017

Sandoz Tested Erelzi’s Suffix On Multiple Fronts

Feb 20 2017

FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say

Feb 16 2017

Related Companies

Ultragenyx Pharmaceutical Inc.

Genentech, Inc.

Spark Therapeutics, Inc.

Additional Topics

United States Drug Review Biosimilars Biologics Regulation Drug Review Profile BioPharmaceutical Blood & Coagulation Disorders Metabolic Disorders Ophthalmic

More from Drug Review Profiles

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window